1 40 1 Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Citation List Month Backlog URL Address <a href="http://doi.org/10.1002/pbc.25035" target="_blank" rel="noreferrer">http://doi.org/10.1002/pbc.25035</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience Publisher An entity responsible for making the resource available Pediatric Blood & Cancer Date A point or period of time associated with an event in the lifecycle of the resource 2014 Subject The topic of the resource adolescent; Child; Female; Humans; Male; retrospective studies; Survival Rate; Adult; Osteosarcoma; Preschool; Disease-Free Survival; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Republic of Korea; Taxoids Creator An entity primarily responsible for making the resource Song Bong Sup; Seo J; Kim Dong H; Lim Jung Sub; Yoo Ji Y; Lee Jun A Description An account of the resource BACKGROUND: We evaluated the efficacy of gemcitabine and docetaxel chemotherapy (GEM + DOC) in children and adolescents with recurrent or refractory osteosarcoma. METHODS: Data of 28 patients (20 male, 8 female) who received gemcitabine (675 or 900 mg/m(2) on days 1 and 8) and docetaxel (100 mg/m(2) on day 8) at Korea Cancer Center Hospital were retrospectively reviewed. RESULTS: Patients (ages 5.0-19.7 years) received a total of 96 courses of chemotherapy (median 3 courses; range, 1-8 courses) and were followed for a median of 14.9 months (range, 0.6-81.4 months). Eleven patients received GEM + DOC after surgery as adjuvant chemotherapy. Seventeen patients received GEM + DOC as palliative therapy, and were eligible for response evaluation; there were three (17.6%) complete response (CR, including two metabolic CR), one (5.9%) partial responses (PR), and three (29.4%) stable disease (SD). The objective response rate (CR + PR) and tumor control rate (CR + PR + SD) were 23.5% and 41.2%, respectively. The median duration of response was 11.2 months (range, 2.8-14.6 months). Dose of gemcitabine (675 or 900 mg/m(2)) did not influence the response rate. Overall survival at 1-year was 53.6 ± 9.4% and patients who received GEM + DOC as adjuvant chemotherapy fared better than those who received GEM + DOC as palliative therapy (72.7 ± 13.4% vs. 35.3 ± 11.6%, P = 0.006). CONCLUSION: GEM + DOC showed some activity in osteosarcoma. Better than expected survival after GEM + DOC was seen both in patients with and without surgery. These results may indicate that dose dense combinations of gemcitabine and taxanes (e.g., gemcitabine + nab-paclitaxel) should be investigated in bone sarcomas. 2014-08 Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1002/pbc.25035" target="_blank" rel="noreferrer">10.1002/pbc.25035</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s). Type The nature or genre of the resource Journal Article 2014 Adolescent Adult Antineoplastic Combined Chemotherapy Protocols Backlog Child Deoxycytidine Disease-Free Survival Female Humans Journal Article Kim Dong H Lee Jun A Lim Jung Sub Male Osteosarcoma Pediatric Blood & Cancer Preschool Republic of Korea Retrospective Studies Seo J Song Bong Sup Survival Rate Taxoids Yoo Ji Y